Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Swami Padmanabhan"'
Autor:
Anders Österborg, Roxanne C. Jewell, Swami Padmanabhan-Iyer, Thomas J. Kipps, Jiří Mayer, Stephan Stilgenbauer, Cathy D. Williams, Andrzej Hellmann, Richard R. Furman, Tadeusz Robak, Peter Hillmen, Marek Trnêný, Martin J.S. Dyer, Magdalena Piotrowska, Tomas Kozak, Ira V. Gupta, Jennifer L. Phillips, Nancy Goldstein, Herbert Struemper, Nedjad Losic, Steen Lisby, William G. Wierda
Publikováno v:
Haematologica, Vol 100, Iss 8 (2015)
Externí odkaz:
https://doaj.org/article/19adce254e934f14a1055ceca752c298
Autor:
Annie Claude Benichou, Monica M. Mita, John Sarantopoulos, Adam Craig, Lyon L. Gleich, Alain C. Mita, Joe Stephenson, John Nemunaitis, Swami Padmanabhan-Iyer, Nisha Nanda
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose Omacetaxine mepesuccinate is a first-in-class cephalotaxine demonstrating clinical activity in chronic myeloid leukemia. A subcutaneous (SC) formulation demonstrated efficacy and safety in phase 1/2 trials in patients previously treated with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25cbdcad70dfe3781060374f162510ae
https://doi.org/10.1007/s00280-012-1963-2
https://doi.org/10.1007/s00280-012-1963-2
Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
Autor:
Tomas Kozak, Geoffrey W. Chan, Randy Davis, Peter Hillmen, Cathy D. Williams, Charlotte A. Russell, Richard R. Furman, Marek Trneny, Nedjad Losic, Anders Österborg, Tadeusz Robak, Magdalena Piotrowska, Thomas J. Kipps, Stephan Stilgenbauer, Joris Wilms, William G. Wierda, Jiří Mayer, Swami Padmanabhan, Andrzej Hellmann, Martin J. S. Dyer
Publikováno v:
Journal of Clinical Oncology. 28:1749-1755
Purpose New treatments are needed for patients with fludarabine- and alemtuzumab-refractory (FA-ref) chronic lymphocytic leukemia (CLL) or patients with fludarabine-refractory CLL with bulky (> 5 cm) lymphadenopathy (BF-ref) who are less suitable for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::705d3202cbac46d2800f50e9aec71497
https://doi.org/10.1200/jco.2009.25.3187
https://doi.org/10.1200/jco.2009.25.3187
Publikováno v:
Future Oncology. 4:359-377
Chronic myeloid leukemia (CML) has led the way for developing rational drug development in cancer. Most cases of CML diagnosed and treated in chronic phase are extremely well controlled with imatinib monotherapy, and primary resistance is very uncomm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a33096d13fddc9bde7eb760bedc945b9
https://doi.org/10.2217/14796694.4.3.359
https://doi.org/10.2217/14796694.4.3.359
Autor:
Thomas J. Kipps, Tomas Kozak, Magdalena Piotrowska, William G. Wierda, Nancy Goldstein, Jiří Mayer, Marek Trnêný, Roxanne C. Jewell, Nedjad Losic, Herbert Struemper, Swami Padmanabhan-Iyer, Stephan Stilgenbauer, Martin J. S. Dyer, Richard R. Furman, Tadeusz Robak, Andrzej Hellmann, Ira Gupta, Peter Hillmen, Cathy D. Williams, Steen Lisby, Jennifer Phillips, Anders Österborg
Publikováno v:
Haematologica.
While fludarabine-based regimens are a standard for treatment of chronic lymphocytic leukemia (CLL), patients who become refractory to fludarabine have had low response rates with salvage therapy and poor survival outcomes.1–3 We reported that ofat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::121209a3f4bc8fe3aa872686f2bb7709
https://doi.org/10.3324/haematol.2014.121459
https://doi.org/10.3324/haematol.2014.121459
Autor:
Nishitha Reddy, Ioannis Karampelas, Asher Chanan-Khan, Robert A. Fenstermaker, Swami Padmanabhan
Publikováno v:
Leukemia & Lymphoma. 48:1228-1230
We describe an unusual case of extramedullary manifestation of multiple myeloma involving the brain. In multiple myeloma, neurological symptoms are usually related to amyloid deposition, hypervisco...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::db1d9a1c5069eccbaf01880df506b290
https://doi.org/10.1080/10428190701272371
https://doi.org/10.1080/10428190701272371
Autor:
Umberto Veronesi, Edith A. Perez, Judy Garber, Stefan Glück, James J. Vredenburgh, Eric Winer, Gabriel N. Hortobagyi, Hyman B. Muss, Carolyn Sartor, Eva Rubin, Rayna Kneuper Hall, Roland Holland, Veronique Cocquyt, Giovanni Rosti, Giammaria Fiorentini, Phillip Nicholas Blondeel, Eli Avisar, P. Murali Doraiswamy, Judith Hurley, Amy Pickar Abernethy, Jennie R. Crews, Merce Jorda, Maria Victoria Velasquez, Monica Maria Yepes, Anna Maria Gonzalez Angulo, Charles L. Bennett, Cristiane Takita, Mohamed A Kharfan-Dabaja, Daniel Morgensztern, Deborah O. Heros, Eloy Roman, Lawrence Negret, Gilberto Lopes, Manuel F. Rosado, Steve Fein, Teresa De Cesare, Sakher Abdullah, Ernesto Ayala, Orfirio M. Sanchez, Carlos Silva, Ervin Gonzalez, Jason Brenner, Jorge E. Silva, Humberto Caldera, Swami Padmanabhan, Susan Moreno, Alicia Ceballos, Talia Donenberg, Susanna Quasem, Kristi L. Lenz
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ca335a9778ba723b70f2690a56016e21
https://doi.org/10.1016/b978-3-437-24260-1.50006-3
https://doi.org/10.1016/b978-3-437-24260-1.50006-3
Autor:
Charlotte A. Russell, Martin J. S. Dyer, Anders Österborg, Richard R. Furman, Marek Trneny, Geoffrey W. Chan, Tadeusz Robak, Randy Davis, William G. Wierda, Stephan Stilgenbauer, Thomas J. Kipps, Nedjad Losic, Jiří Mayer, Joris Wilms, Cathy D. Williams, Tomas Kozak, Magdalena Piotrowska, Andrzej Hellmann, Swami Padmanabhan, Peter Hillmen
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 10:157
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c4ef0c096af4d6090d8a179a53e02a11
https://doi.org/10.3816/clml.2010.n.024
https://doi.org/10.3816/clml.2010.n.024
Autor:
Nedjad Losic, Marek Trneny, Martin J. S. Dyer, Anders Österborg, Stephan Stilgenbauer, Geoffrey W. Chan, Randy Davis, Tomas Kozak, Joris Wilms, Richard R. Furman, Tadeusz Robak, Cathy D. Williams, Magdalena Piotrowska, Charlotte A. Russell, Peter Hillmen, Swami Padmanabhan, Andrzej Hellmann, Thomas J. Kipps, William G. Wierda, Jiří Mayer
Publikováno v:
Clinical Lymphoma and Myeloma. 9:E36
Brief Abstract Ofatumumab, a novel CD20 monoclonal antibody, produces high response rates regardless of prior rituximab exposure in patients with fludarabine- and alemtuzumab-refractory or bulky fludarabine-refractory chronic lymphocytic leukemia. Fu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::27f40e04e23b95ebfa0d356782060ae7
https://doi.org/10.3816/clm.2009.n.098
https://doi.org/10.3816/clm.2009.n.098
Autor:
Cathy D. Williams, Richard R. Furman, Tadeusz Robak, Michael Arning, Martin J. S. Dyer, Jiri Mayer, Peter Hillmen, Magdalena Piotrowska, Charlotte A. Russell, Geoffrey W. Chan, Randy Davis, Joris Wilms, Thomas J. Kipps, Marek Trneny, Roxanne C. Jewell, Andrzej Hellmann, William G. Wierda, Tomas Kozak, Stephan Stilgenbauer, Swami Padmanabhan, Anders Österborg, Birgitte Biilmann Ronn, Nedjad Losic
Publikováno v:
Blood. 114:3433-3433
Abstract 3433 Poster Board III-321 Introduction Monoclonal antibody (mAb) therapies represent an important clinical advance for patients (pts) with CLL, yet little is known about the pharmacokinetics (PK) and pharmacodynamics of mAb therapy in these
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c8ef938fea852688cc250c7d4a8258c0
https://doi.org/10.1182/blood.v114.22.3433.3433
https://doi.org/10.1182/blood.v114.22.3433.3433